BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Angiogenesis
,
Obesity
,
Intestine
,
Avian flu virus
,
Tamoxifen
,
rs6983267
,
FOXP1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PD L2
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
B cells CD80 and PDL2 double and single positive subpopulations
Melanoma tumor biopsies from patients treated with anti-PD1 therapy
Mammary epithelial cells and acute myeloid leukemia U938 cells with siRNA mediated STAG2 knockdown
Macrophages from blood or bone marrow and mesenchymal stem cell-educated macrophages (MEMs)
Lung squamous cell carcinoma UN-SSC680 cells with CRISPR/Cas9-induced PTEN knockout (null mutant)
Explore Curated Studies Results
Literature
Most Relevant Literature
Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced …
EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Myeloid dendritic cells can kill T cells during chronic hepatitis C virus infection.
Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expres…
Programmed death ligand 2 in cancer-induced immune suppression.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma
Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumo…
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcino…
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib i…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ